Mylan Pharmaceuticals Inc. et al v. Sanofi-Aventis U.S. LLC et al.

Docket No.
2:23-cv-00836
District Court
Pennsylvania Western

Goal

  • Award damages

Issues

Why this Matters:

The plaintiffs argue that defendants improperly listed certain patents in the Orange Book to maintain exclusivity and block other generics from entering the market in violation of federal patent and antitrust law. Patent abuses can distort the market for prescription drugs and drive up prices for consumers.

Potential Impact:

Improper patent listings in the Orange Book can undermine fair competition and prohibit or delay consumers from accessing lower-cost generic drugs.

News And Analysis (1)

16 Major Filings

View More

Related Litigation

Current Status

Briefing is ongoing

Legal Issues

Sherman Act, Clayton Act, New Jersey Antitrust Act, Tortious Inducement of Refusal to Deal

Amicus Briefs for Plaintiff(s)

Federal Trade Commission

Topic(s)

Orange Book Patent Listings

Date Filed
May 18, 2023
Case Type
Civil
Court Type
District Court
Court
Pennsylvania Western
Judge
Hornak, Mark R. Appointed By: Barack Obama
Plaintiff(s)
Mylan Pharmaceuticals Inc.; Mylan Specialty L.P.; Mylan Inc.
Lead Counsel For Plaintiff(s)
John A. Schwab Attorney at Law, LLC
Defendant(s)
Sanofi-Aventis U.S. LLC; Sanofi S.A.; Aventis Pharma S.A.; Sanofi-Aventis Puerto Rico Inc.
Lead Counsel for Defendant(s)
Jones Day